Minerva Neurosciences
NERV
46 hedge funds and large institutions have $42.9M invested in Minerva Neurosciences in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 25 closing their positions.
122% more call options, than puts
Call options by funds: $1.05M | Put options by funds: $472K
0.75% less ownership
Funds ownership: 7.97% → 7.22% (-0.75%)
24% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 17
32% less capital invested
Capital invested by funds: $63.2M → $42.9M (-$20.2M)
32% less funds holding
Funds holding: 68 → 46 (-22)
88% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$627K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$276K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$188K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$186K |
| 5 |
AC
Armistice Capital
New York
|
+$165K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$968K |
| 2 |
Morgan Stanley
New York
|
-$681K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$616K |
| 4 |
Two Sigma Investments
New York
|
-$608K |
| 5 |
Two Sigma Advisers
New York
|
-$576K |
NERV Hedge Fund Activity: Q3 2021 in Review
46 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Minerva Neurosciences (NERV) for Q3 2021, worth a combined $42.9M — down 32% from $63.2M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of NERV and 3 opened new positions — a net loss of 22 holders — while 17 trimmed existing stakes and 13 added.
The largest buyer was Assenagon Asset Management, adding an estimated $627K. The largest seller was Millennium Management, cutting an estimated $968K.
- 46 institutional investors held Minerva Neurosciences (NERV) as of Q3 2021, down from 68 in Q2 2021.
- Funds reported $42.9M of Minerva Neurosciences stock for Q3 2021, down 32% quarter-over-quarter.
- 3 funds opened new Minerva Neurosciences positions in Q3 2021 and 25 closed out, a net change of -22 holders.
- The largest Minerva Neurosciences buyer in Q3 2021 was Assenagon Asset Management, an estimated $627K added.
- The largest Minerva Neurosciences seller in Q3 2021 was Millennium Management, an estimated $968K sold.
Based on aggregated 13F filings for Q3 2021.